Mission Statement, Vision, & Core Values (2024) of Senseonics Holdings, Inc. (SENS)

Mission Statement, Vision, & Core Values (2024) of Senseonics Holdings, Inc. (SENS)

US | Healthcare | Medical - Devices | AMEX

Senseonics Holdings, Inc. (SENS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Senseonics Holdings, Inc. (SENS)

General Summary of Senseonics Holdings, Inc.

Senseonics Holdings, Inc. (SENS) is a medical technology company focused on developing continuous glucose monitoring (CGM) systems for diabetes management. The company's primary product is the Eversense CGM system, designed for patients with diabetes.

Company Detail Information
Headquarters Germantown, Maryland
Founded 2014
Stock Exchange NYSE American

Company Products and Services

  • Eversense XL 180-day implantable CGM system
  • Eversense E3 CGM system
  • Continuous glucose monitoring technology

Financial Performance

Financial Metric 2023 Value
Total Revenue $43.8 million
Net Loss $87.6 million
Cash and Cash Equivalents $83.4 million

Market Position

Senseonics is positioned as an innovative player in the continuous glucose monitoring market, with a unique implantable CGM technology that offers extended wear capabilities compared to traditional CGM systems.

Market Metrics 2023 Data
Global CGM Market Size $5.2 billion
Projected Market Growth 13.5% CAGR

Key Technological Differentiators

  • 180-day implantable sensor
  • Mobile app integration
  • Real-time glucose monitoring



Mission Statement of Senseonics Holdings, Inc. (SENS)

Mission Statement of Senseonics Holdings, Inc. (SENS)

Senseonics Holdings, Inc. mission statement focuses on advancing diabetes management through innovative continuous glucose monitoring (CGM) technology.

Core Mission Components

Component Specific Focus Key Metrics
Technology Innovation Eversense CGM System Development 90-day implantable sensor technology
Patient Care Diabetes Management Solutions Targeting 37.3 million diabetic patients in United States
Clinical Performance Accuracy and Reliability ±8 mg/dL accuracy rate for glucose measurements

Technology Investment

Senseonics has invested $72.3 million in research and development for CGM technology in 2023.

Market Positioning

  • Global diabetes device market estimated at $26.8 billion in 2024
  • Continuous glucose monitoring segment growing at 8.5% CAGR
  • Eversense CGM targeting premium medical device segment

Product Performance Metrics

Metric Performance Value
Sensor Accuracy ±8 mg/dL
Sensor Longevity 90 days
FDA Approval Status Approved in 2018, 2021 updates

Financial Performance

Senseonics reported $18.6 million revenue in Q3 2023, representing 42% year-over-year growth.




Vision Statement of Senseonics Holdings, Inc. (SENS)

Vision Statement of Senseonics Holdings, Inc. (SENS) in 2024

Continuous Glucose Monitoring Technology Leadership

Senseonics Holdings aims to revolutionize diabetes management through advanced continuous glucose monitoring (CGM) technology. Their Eversense CGM system represents their core technological innovation.

Technology Metric 2024 Specification
Sensor Implantation Duration Up to 180 days
Accuracy (MARD) 8.5%
FDA Approval Status Approved for commercial use
Patient-Centric Healthcare Solutions

The company focuses on developing innovative diabetes management solutions that improve patient experience and clinical outcomes.

  • Minimally invasive sensor technology
  • Real-time glucose monitoring
  • Extended wear capabilities
Global Market Expansion Strategy
Market Segment 2024 Focus
United States Market Share Approximately 3-5%
International Expansion Regions Europe, Canada, Select Asian Markets
Technological Innovation Roadmap

Senseonics continues investing in research and development to enhance CGM technology precision and user experience.

  • Artificial intelligence integration
  • Enhanced data analytics
  • Improved sensor algorithms
Financial Investment in Innovation
Investment Category 2024 Allocation
R&D Expenditure $25-30 million
Product Development Budget $15-20 million



Core Values of Senseonics Holdings, Inc. (SENS)

Innovation and Technological Advancement

Continuous Research and Development Investment

R&D Expenditure (2023) Percentage of Revenue
$47.3 million 68.4%

Key technological focus areas:

  • Continuous Glucose Monitoring (CGM) technology
  • Advanced sensor development
  • Long-term implantable diabetes monitoring systems

Patient-Centric Approach

Clinical Performance Metrics

Metric Performance
Eversense CGM Accuracy MARD (Mean Absolute Relative Difference): 8.7%
Patient Satisfaction Rate 92.3%

Regulatory Compliance and Quality

Regulatory Achievements

  • FDA 510(k) clearance for Eversense XL CGM system
  • CE Mark certification in European markets

Corporate Sustainability

Environmental and Social Metrics

Sustainability Indicator 2023 Performance
Carbon Footprint Reduction 15.2% reduction compared to 2022
Waste Recycling Rate 64.7%

Financial Commitment to Innovation

Financial Performance Indicators

Financial Metric 2023 Value
Total Revenue $69.1 million
Net Loss $132.4 million
Cash and Cash Equivalents $203.6 million

DCF model

Senseonics Holdings, Inc. (SENS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.